Clinical Trial

A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase 1, randomized, blinded, placebo controlled, single-ascending dose (SAD) and multiple-ascending dose (MAD) study of BBT001 in healthy volunteers (HVs) and adult patients with moderate to severe Atopic Dermatitis (AD).
Protocol Amendment History 4 changes
critical Primary endpoint(s) modified 2026-07-10
notable Enrollment increased: 198 -> 237 participants 2026-07-10
notable Trial sites expanded: 7 -> 14 locations 2026-07-10
notable Primary completion pushed: 2026-08-21 -> 2027-02-28 2026-07-10
Trial Details
NCT Number NCT06808477
Lead Sponsor Bambusa Therapeutics
Conditions Atopic Dermatitis
Enrollment 237 participants
Start Date 2025-02-27
Primary Completion 2027-02-28 (estimated)
Study Completion 2027-02-28 (estimated)
Updated on ClinicalTrials.gov 2026-08-13